Program Summary
Efforts to develop novel biologic therapeutics have provided critical resources to enable warfighter readiness and counter existing and emerging biothreats; however, current delivery modalities limit biologics’ efficacy and rapid deployment. The goal of DARPA’s new Hermes program is to overcome the challenges associated with broad, intracellular delivery of biologics to diverse cell and tissue types by developing new delivery modalities that provide systemic distribution with limited negative side effects. Delivery vehicles developed under the Hermes program will be cargo agnostic—enabling the rapid deployment of any type of medical countermeasure against any threat.